Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept dose-to-target tapering in juvenile idiopathic arthritis
NL-OMON20690Not yet recruiting
- Sponsor
- Jan van Breemen Instituut, Reade
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of etanercept in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Jan van Breemen Instituut, Reade. Primary endpoint: Proportion maintaining minimal disease activity after dose interval prolongation. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON20690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20690.